Latest From CSL Ltd.
Baxter, Ariad, Diurnal. Kyowa Kirin and AB Science are among the companies that will shortly find out what remaining concerns the European Medicines Agency’s key advisory panel, the CHMP, has regarding products of theirs that are under review.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
IPOs are up, hemophilia is driving company pipelines, speculation over Pascal Soriot's career plans drive billions from AstraZeneca's market capitalization, Sanofi signs a $650m vaccine deal, private equity bidders up their offer for Stada and earnings season kicks off. Commercial capsule rounds up recent business news and trends reported by sister publication Scrip.
In agreeing a $650m+ deal to acquire privately owned Protein Sciences, Sanofi is defending its market dominance in influenza vaccinations by adding an approved non-egg based product. The purchase may also help it defend its position in the section of the market targeting elderly patients, since its current trivalent offering is threatened by a rival quadrivalent product from Seqirus.
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Infectious & Viral Diseases
- Commonwealth Serum Laboratories
- Parent & Subsidiaries
- CSL Ltd.
- Senior Management
- Paul Perreault, CEO & Mng. Dir.
- Contact Info
Phone: (61) 3 9389 1911
45 Poplar Rd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.